We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to ...
Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...
Medtronic's stock has lost around a third of its value since late 2022. However, stock prices for longtime dividend growers ...
Boston Scientific (NYSE: BSX) announced new study findings demonstrating the superiority of its Farapulse pulsed field ...
Medtronic (NYSE:MDT) shares snapped seven straight days of losses as the stock closed 0.85% higher, at $88.98 on Thursday. ...
Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut ...
Explore more
Medtronic’s top ventilator executive began fielding pleas from world leaders' representatives five years ago, as pressure ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolutâ„¢ ...
Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...
The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", ...
3d
Zacks Investment Research on MSNMedtronic (MDT) Increases Despite Market Slip: Here's What You Need to KnowMedtronic (MDT) closed the latest trading day at $88.98, indicating a +0.85% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 0.33%.
Medtronic’s diverse portfolio faces financial growth concerns. Learn why MDT stock is a HOLD, offering stability but limited growth in the short term.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results